 |
Pressbox: Agennix AG
- Press release BoxID 195730
GPC Biotech gibt Kündigung des Entwicklungs- und Lizenzvertrags für Satraplatin durch Celgene bekannt
(PresseBox) Martinsried/München und US-Standort in Princeton, N.J., 07.08.2008, GPC Biotech AG (Deutsche Börse: GPC; NASDAQ: GPCB) wurde heute von Celgene Corporation über deren Entscheidung informiert, die Kündigung des Entwicklungs- und Lizenzvertrags...
Observe this press release
We will be glad to notify you per E-Mail when inactive Press releases are released by the publisher. Observe the corresponding messages:
Company info
Agennix AG
Fraunhoferstraße 20
D-82152 Martinsried
The specified publisher (see company information at right) is responsible for the above press release. Normally, this is also the author of the press releases, as well as attached image, audio or information material. The unn | UNITED NEWS NETWORK GmbH accepts no responsibility for accuracy, or completeness of the displayed press release. Also, regarding transmission errors or other disorders shall be liable only in cases of willful intent or gross negligence.
The use of archived information for personal and journalistic use is normally free of charge. Please clarify any copyright issues regarding further use of material with the specified publisher. Upon publication, please send a courtesy copy to service@pressebox.de.
A systematic storage of these data as well as the use of a part or the whole of this data base is subject to written appoval by the unn | UNITED NEWS NETWORK GmbH.
The use of archived information for personal and journalistic use is normally free of charge. Please clarify any copyright issues regarding further use of material with the specified publisher. Upon publication, please send a courtesy copy to service@pressebox.de.
A systematic storage of these data as well as the use of a part or the whole of this data base is subject to written appoval by the unn | UNITED NEWS NETWORK GmbH.
